Sichuan Goldstone Asia Pharmaceutical Inc. (SHE:300434)
China · Delayed Price · Currency is CNY 13.16
+0.75 (6.04%)
Oct 9, 2026, 1:35 PM CST
SHE:300434 Revenue
Sichuan Goldstone Asia Pharmaceutical had revenue of 159.07M CNY in the quarter ending June 30, 2026, a decrease of -20.53%. This brings the company's revenue in the last twelve months to 1.04B, down -3.24% year-over-year. In the year 2025, Sichuan Goldstone Asia Pharmaceutical had annual revenue of 1.04B, down -5.80%. That makes Sichuan Goldstone Asia Pharmaceutical the 19,322nd largest company in the world by revenue and 3,530th in China.
Revenue (ttm)
1.04B
Revenue Growth
-3.24%
P/S Ratio
4.81
Revenue / Employee
578.20K
Employees
1,794
Market Cap
5.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.04B | -63.96M | -5.80% |
| Dec 31, 2024 | 1.10B | -106.84M | -8.84% |
| Dec 31, 2023 | 1.21B | -33.40M | -2.69% |
| Jan 1, 2023 | 1.24B | 189.10M | 17.95% |
| Jan 1, 2022 | 1.05B | 276.21M | 35.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| China State Construction Engineering Corporation | 1.95T |
| Contemporary Amperex Technology | 521.73B |
| China CSSC Holdings | 170.87B |
| Beijing-Shanghai High-Speed Railway | 43.89B |
| Guangdong Dongpeng Holdings | 5.55B |
| Shenzhen INVT Electric Co.,Ltd | 4.61B |
| Hangzhou Youngsun Intelligent Equipment | 4.20B |
| Yutong Heavy Industries | 3.33B |